Mucositis
Drug research and approvals for mucositis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 63 studies of mucositis are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 0 approved and 5 open orphan designations naming it.
- Recruiting worldwide: 63
- Trials authorized in Canada: 2
- FDA orphan approvals: 0
- EU medicines: 0
- Systemic Inflammatory and Metabolic Biomarkers of Peri-Implant Diseases in Postmenopausal WomenNCT07950085 · Not reported · Kübra Hazal Bilgin · starts Oct 1, 2026
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyNCT07885033 · Not applicable · UNCANCER LLC · starts Nov 1, 2026
- Study of a Copaiba-Based Mouthwash Combined With Low-Level Laser Therapy in the Prevention of Oral Mucositis in…NCT07810530 · Phase 2 · Instituto Nacional de Cancer, Brazil · starts Mar 29, 2026
- Home-Use Dual-Light Antibacterial Photodynamic Therapy for Peri-Implant Mucositis in Full-Arch Implant ProsthesesNCT07763431 · Not applicable · University of Medicine and Pharmacy at Ho Chi Minh City · starts Oct 19, 2026
- Impact of Smoking on Immune Responses in Peri-implant Health and DiseaseNCT07750171 · Not reported · Gazi University · starts Jun 1, 2026
- Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced MucositisNCT07736495 · Phase 2 / Phase 3 · Ain Shams University · starts Jul 27, 2026
- The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral MucosaNCT07723612 · Not applicable · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · starts Jun 1, 2026
- Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant MucositisNCT07722715 · Not applicable · Freiburger Medizintechnik GmbH · starts Feb 14, 2026
- Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to TransplantNCT07709195 · Phase 2 · Tata Memorial Centre · starts Oct 30, 2024
Approved 1
- PaliferminFibroblast growth factor receptor 2 agonist
Phase 3 8
- CisplatinDNA inhibitor
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- AcetylcysteineGlutathione precursor
- DoxepinNorepinephrine transporter inhibitor
- HydromorphoneMu opioid receptor agonist
- TriclosanBacterial enoyl-[acyl-carrier-protein] reductase inhibitor
- Glutamine
- Sodium fluoride
Phase 2 12
- TK-112690
- Zinc sulfate
- AcetaminophenCyclooxygenase inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- MorphineMu opioid receptor agonist
- LidocaineSodium channel alpha subunit blocker
- ChlorhexidineCell membrane inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- GabapentinVoltage-gated calcium channel modulator
- Folic acid
- Lipoic acid, alpha
Phase 1 or earlier 4
- Triamcinolone acetonideGlucocorticoid receptor agonist
- PhenylephrineAdrenergic receptor alpha-1 agonist
- Licorice
- Curcumin
How its trials ended
504 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 88 whose ending is known, 27% met their primary endpoint, 7% missed it and 66% stopped early.
- Completed, result not reported23847%
- Ongoing9920%
- Status unknown7916%
- Stopped: other or unclear326%
- Met its primary endpoint245%
- Stopped: enrollment or feasibility112%
- Missed its primary endpoint61%
- Stopped: funding61%
- Stopped: sponsor or business decision51%
- Stopped: lack of efficacy31%
- Stopped: safety1<1%
| Apr 7, 2025 | A single-centre, prospective, observational and proof-of-principle study of prevora's ability to treat peri-implant mucositis.Chlorhexidine | CHX Technologies | Pending |
| Aug 8, 2018 | A phase 3, randomized, double-blind, placebo-controlled, multi-center study of the superoxide dismutase mimetic GC4419 to reduce severe oral mucositis (SOM)…Avasopasem (GC4419) | Galera Therapeutics | Ongoing |
| Feb 27, 2008 | Manganese superoxide dismutase mimeticPrevention of radiation- or chemotherapy-induced oral mucositis in cancer patients | Galera Therapeutics, LLC | Designated |
| Jan 29, 2004 | Recombinant human fibroblast growth factor-20Treatment of radiation induced oral mucositis | CuraGen Corporation | Designated |
| May 18, 1998 | Benzydamine hydrochlorideProphylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer. | Angelini Pharmaceuticals, Inc. | Designated |
| Jul 15, 1993 | SucralfateTreatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer. | Fuisz Technologies, Ltd. | Designated |
| Aug 18, 1986 | Chlorhexidine gluconate mouthrinseFor use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow… | Procter & Gamble Company | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA